Coronary Artery Disease and Myocardial Infarction

AHA 22: RESPECT EPA: Eicosapentaenoic Acid for Prevention of Coronary Artery Disease

Hiroyuki Daida, Saahil A Jumkhawala,

Watch time: 14m 14s
AHA 22 Late-Breaker Discussion: The PRECISE Trial

Pamela S Douglas, Harriette Van Spall,

Watch time: 14m 57s
Radcliffe & CardioNerds @AHA22: Reduction of Lp(a) With Small Interfering RNA

Gurleen Kaur, Michelle O'Donoghue,

Watch time: 14m 29s
Radcliffe & CardioNerds @AHA22: Reduction of Triglycerides With Pemafibrate

Aruna D Pradhan, Gurleen Kaur,

Watch time: 14m 25s
EP 78: Your Guide to Lipoprotein(a) with Dr. Salim S Virani

Salim S Virani, Ankur Kalra,

Listen time: 46:28
TCT 22: FAME 3: FFR-Guided PCI Vs CABG in Pts With Multivessel CAD

Yuhei Kobayashi,

Watch time: 07:21
FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2m 56s
FOURIER-OLE: The Trial in Context

Marc S Sabatine,

Watch time: 3m 24s
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue,

Watch time: 3m 30s

Yassir Javaid, , , et al

Watch time: 1h 6m (4 videos)
4 Lipid Late-breaker Highlights from ACC.22 with Dr Erin Michos

Erin D Michos,

Secondary Analysis of CANTOS Finds LDL & HDL Predict Residual Risk of Atherosclerotic Events

Paul M Ridker,

Heather Currie , Christine Williams ,

Edward T Carreras , Donna M Polk ,

FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2m 56s
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue,

Watch time: 3m 30s

Charles H Hennekens , Danielle Hollar , Arthur S Agatston ,

Sergio Fazio ,

Marc Sirol ,

Abdulah Alrifai , Mohamad Kabach , Jonathan Nieves , et al

Donald E Cutlip ,

Antonio Gutierrez , Sunil V Rao ,

Marsha M Neumyer , Bill Bertolino ,

Yassir Javaid, , , et al

Watch time: 1h 6m (4 videos)

Media

AHA 22: RESPECT EPA: Eicosapentaenoic Acid for Prevention of Coronary Artery Disease

Hiroyuki Daida, Saahil A Jumkhawala,

Watch time: 14m 14s
AHA 22 Late-Breaker Discussion: The PRECISE Trial

Pamela S Douglas, Harriette Van Spall,

Watch time: 14m 57s
Radcliffe & CardioNerds @AHA22: Reduction of Lp(a) With Small Interfering RNA

Gurleen Kaur, Michelle O'Donoghue,

Watch time: 14m 29s
Radcliffe & CardioNerds @AHA22: Reduction of Triglycerides With Pemafibrate

Aruna D Pradhan, Gurleen Kaur,

Watch time: 14m 25s
EP 78: Your Guide to Lipoprotein(a) with Dr. Salim S Virani

Salim S Virani, Ankur Kalra,

Listen time: 46:28
TCT 22: FAME 3: FFR-Guided PCI Vs CABG in Pts With Multivessel CAD

Yuhei Kobayashi,

Watch time: 07:21
FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2m 56s
FOURIER-OLE: The Trial in Context

Marc S Sabatine,

Watch time: 3m 24s
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue,

Watch time: 3m 30s

Yassir Javaid, , , et al

Watch time: 1h 6m (4 videos)
4 Lipid Late-breaker Highlights from ACC.22 with Dr Erin Michos

Erin D Michos,

Secondary Analysis of CANTOS Finds LDL & HDL Predict Residual Risk of Atherosclerotic Events

Paul M Ridker,

ACC 22: PACMAN-AMI Shows Reduced Plaque Regression in AMI Patients Treated with Alirocumab

Lorenz Räber,

ACC 22: Magnitude & Duration of Effects of a siRNA Targeting Lp(a)

Steven E Nissen,

ACC 22: Results from the TRANSLATE-TIMI 70 Trial

ACC 22: FAME 3 Suggests CABG Outperforms FFR-Guided PCI in Patients with Multivessel Disease

Frederik Zimmermann,

ACC 2022 Late-breaker Discussion: The SuperWIN Trial

Dylan L Steen, Harriette Van Spall,

RIPCORD 2: FFR During Angiography Did Not Improve Patient Outcomes

Nick Curzen,

ACC 2021: Findings From the RESCUE Trial

Paul M Ridker,

ACC 2021 Discussion: The STRENGTH Study

Steven E Nissen, Harriette Van Spall,

What to Expect at TCTAP 2021

Bill D Gogas, Duk-Woo Park,

AHA 2020: The STRENGTH Trial

AHA 2020: Evinacumab safety and efficacy in HoFH

TCT Connect 2020 Discussion: The VOYAGER PAD Study

Mirvat Alasnag, ,

ESC 2020: APOC-III Reduction in Cardiovascular Disease

Jean-Claude Tardif,

View From The Thoraxcenter: What's Hot at ESC 2020

Nicolas M Van Mieghem, Joost Daemen,

ACC 2020: Inclisiran Potently and Durably Reduces Ldl-c

ACC 2020: Primary Results of the Voyager PAD Trial

Marc P Bonaca,

AHA 2019: Empagliflozin on Erythropoietin Levels

David Mazer,

AHA 2019: Updates from the EVAPORATE Study

Matthew J Budoff,

Articles

Coronary CT Angiography-derived FFR

Lavanya Cherukuri

,

Divya Birudaraju

,

Matthew J Budoff

,

Published:

23 April 2021

Citation:

US Cardiology Review 2021;15:e06.

DOI:

https://doi.org/10.15420/usc.2020.24
  • Views: Views 1467
  • Downloads: Downloads 70

Current Evidence and Future Directions of PCSK9 Inhibition

Jiaqian Xu

,

Michael D Shapiro

,

Published:

16 February 2021

Citation:

US Cardiology Review 2021;15:e01.

DOI:

https://doi.org/10.15420/usc.2020.17
  • Views: Views 2875
  • Downloads: Downloads 144

HDL Cholesterol and Adverse Outcomes

Marc P Allard-Ratick

,

Pratik Sandesara

,

Arshed A Quyyumi

,

Laurence S Sperling

,

Published:

12 March 2019

Citation:

US Cardiology Review 2019;13(1):49–53

DOI:

https://doi.org/10.15420/usc.2019.3.2
  • Views: Views 2429
  • Downloads: Downloads 26
  • Citations: 5

Role of Drug-coated Balloons in Small-vessel Coronary Artery Disease

Michael Megaly

,

Marwan Saad

,

Emmanouil S Brilakis

,

Published:

12 March 2019

Citation:

US Cardiology Review 2019;13(1):16–20

DOI:

https://doi.org/10.15420/usc.2019.4.1
  • Views: Views 1174
  • Downloads: Downloads 28
  • Citations: 4